Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates

Background: Our previous studies showed the safe preventive and therapeutic effects of immunization using the nanoliposomal antiPCSK9 vaccine called “Liposomal Immunogenic Fused PCSK9-Tetanus plus Alum adjuvant” (L-IFPTA), in mouse models of atherosclerosis. Here we aimed to ascertain the immunogeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Momtazi-Borojeni, Amir Abbas, Jaafari, Mahmoud R., Banach, Maciej, Gorabi, Armita Mahdavi, Sahraei, Hedayat, Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309966/
https://www.ncbi.nlm.nih.gov/pubmed/34358164
http://dx.doi.org/10.3390/vaccines9070749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309966/
https://www.ncbi.nlm.nih.gov/pubmed/34358164
http://dx.doi.org/10.3390/vaccines9070749

Ejemplares similares